Nuvaxovid 2025-2026 Formula now approved in Japan triggering Takeda milestone payment – Novavax

Novavax Inc. announced a milestone payment from Takeda has been triggered by regulatory approval in Japan for Novavax’s Covid-19 vaccine Nuvaxovid 2025-2026 Formula (Intramuscular Injection 1 mL) formulated to target SARS-CoV-2 Omicron LP.8.1 as an initial immunization (first and second vaccination) for those aged six years or older and a booster immunization (after the third vaccination) for those aged 12 years or older.

Novavax is eligible to receive royalties on net sales of Nuvaxovid from Takeda this vaccination season. A portion of the milestone payment can be credited towards future royalty payments. These payments are part of the updated and significantly improved terms of Novavax’s collaboration and licensing agreement with Takeda, announced earlier this year.

“By achieving this milestone in our agreement with Takeda, we are ensuring access to a protein-based, non-mRNA COVID-19 vaccine option in Japan, the third largest healthcare market in the world, while simultaneously advancing our corporate growth strategy,” said John C. Jacobs, President and Chief Executive Officer, Novavax. “We are pleased that Japan’s Ministry of Health, Labour and Welfare has approved our vaccine, Nuvaxovid, which has a history of clinical use in many countries around the world and provides value for public health.”